The UCLA Radioactive Drug Research Committee (RDRC) operates under the provisions of 21 CFR 361.1 and is responsible for the evaluation of all proposals that involve the use of radioactive drugs in humans without an IND when the drug is administered under the following conditions:
- The research is considered basic science research and is done for the purpose of advancing scientific knowledge. Under § 361.1(a), this type of research is:
- intended to obtain basic information regarding the metabolism (including kinetics, distribution, dosimetry, and localization) of a radioactive drug or regarding human physiology, pathophysiology, or biochemistry,
- not intended for immediate therapeutic, diagnostic or similar purposes (e.g. preventive benefit to the study subject from the research), and
- not intended to determine the safety and effectiveness of a radioactive drug in humans.
The RDRC meets quarterly.
Additional Information
Help and Tutorials
Committee Membership
Voting Members
| Name | Department |
|---|---|
| Chair – Jorge Barrio, PhD | Molecular & Medical Pharmacology |
| Vice-Chair – Magnus Dahlbom, PhD | Molecular & Medical Pharmacology |
| Robert Acha, PhD | EH&S – Radiation Safety Officer |
| Nzhde Agazaryan, PhD, DABR | Radiation Oncology |
| Gholam Berenji, MD | VA Healthcare System |
| Johnathan Chen, MD | Pediatric Radiation |
| Antoinette Gomes, MD | Radiology |
| Sung-Cheng Huang, ScD | Molecular & Medical Pharmacology |
| Jie Liu, PhD | Molecular & Medical Pharmacology |
| Nagichettiar Satyamurthy, PhD | Molecular & Medical Pharmacology |
Non-voting Members
| Name | Department |
|---|---|
| Dina Boktor | RPC – Radiation Safety Committees |
| Mark Mimnaugh | Office of the Human Research Protection Program |
| Sabrina Perez | RPC – Radiation Safety Committees |
| Mary Rosenbluth | EH&S – Alternate Radiation Safety Officer |